---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-24-000092"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:53:15.412612+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds

## Summary
- GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.
- Revenue $418.2M, up 9.7% reported, 2.3% organic; organic ex-Boston +0.3%. Adjusted gross margin 65.2% (down from 67.6%).
- Codman Specialty Surgical rev $301.8M (+11.3% reported, +0.9% organic). Tissue Technologies $116.4M (+5.6% reported, +5.7% organic; -1% ex-Boston).
- FY2024 guidance cut: revenue $1.609-1.629B, adjusted EPS $2.41-2.57. Cites temporary shipping holds and investments in quality/GMP compliance.
- Received PMA approvable for SurgiMend pending GMP certification; Braintree facility operational readiness expected H1 2026.

## SEC filing metadata
- accession: 0000917520-24-000092
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752024000092/0000917520-24-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752024000092/iart-20240729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-24-000092
- JSON: https://secwatch.observer/filing/0000917520-24-000092.json
- Plain text: https://secwatch.observer/filing/0000917520-24-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.